A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company
RARECast - Un pódcast de RARECast - Jueves
Categorías:
Stan Abel, CEO of ProJenX, about ALS, the company’s lead therapeutic candidate prosetin, and the company’s ongoing relationship with Project ALS and Columbia University.
